Standout Papers

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme 2003 2026 2010 2018 1.0k
  1. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme (2007)
    James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology
  2. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020)
    David A. Reardon, Alba A. Brandes et al. JAMA Oncology
  3. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma (2010)
    John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology
  4. Recurrent Glioblastoma Treated with Recombinant Poliovirus (2018)
    Annick Desjardins, Matthias Gromeier et al. New England Journal of Medicine
  5. Phase II Trial of Gefitinib in Recurrent Glioblastoma (2003)
    Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology
  6. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group (2015)
    Hideho Okada, Michael Weller et al. The Lancet Oncology
  7. Brain immunology and immunotherapy in brain tumours (2019)
    John H. Sampson, Michael D. Gunn et al. Nature reviews. Cancer
  8. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 (2017)
    Antonio Omuro, Gordana Vlahovic et al. Neuro-Oncology
  9. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study (2015)
    James M. Schuster, Lawrence D. Recht et al. Neuro-Oncology

Immediate Impact

15 by Nobel laureates 14 from Science/Nature 109 standout
Sub-graph 1 of 18

Citing Papers

mRNA-based therapeutics: looking beyond COVID-19 vaccines
2024 StandoutNobel
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
2024 Standout
15 intermediate papers

Works of John H. Sampson being referenced

Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody
2013
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
2012
and 11 more

Author Peers

Author Last Decade Papers Cites
John H. Sampson 9662 11415 7645 377 24.1k
Eric C. Holland 6186 9873 4629 227 25.2k
Allan H. Friedman 5537 11984 3237 340 25.2k
Owen N. Witte 7240 9025 9441 350 35.5k
David A. Reardon 8565 20314 4800 552 33.1k
Raymond Sawaya 7808 11284 2465 349 27.7k
Kenneth Aldape 6478 10822 3180 360 26.8k
Mark Raffeld 13976 5464 7669 423 26.9k
Christine Marosi 4415 14391 2334 193 23.8k
Henry S. Friedman 8859 21140 4115 564 37.6k
Roger E. McLendon 12748 18272 5233 325 41.0k

All Works

Loading papers...

Rankless by CCL
2026